Curcumin and cancer: An "old-age" disease with an "age-old" solution

Cancer Letters

Volumn 267, Issue 1, 2008, Pages 133-164

  Anand, Preetha ^a   Sundaram, Chitra ^a   Jhurani, Sonia ^a   Kunnumakkara, Ajaikumar B ^a   Aggarwal, Bharat B ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Anticancer activity; Cancer; Chemoprevention; Chemosensitization; Curcumin; Inflammation; Radiosensitization

Indexed keywords

4 ETHOXYCARBONYLETHYL CURCUMIN; ANTINEOPLASTIC AGENT; BISDEMETHOXY CURCUMIN DERIVATIVE; CATECHIN; CELECOXIB; CISPLATIN; CURCUMA LONGA EXTRACT; CURCUMIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DIACETYLMETHOXYCURCUMIN; DOCETAXEL; DOXORUBICIN; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; IFOSFAMIDE; ISOXAZOLE DERIVATIVE; MELPHALAN; NANOCURCUMIN; OXALIPLATIN; PACLITAXEL; PHENYL ISOTHIOCYANATE; PIPERINE; PLACEBO; PREDNISONE; SULINDAC; TETRAHYDROCURCUMIN; TRIACETYLMETHOXYCURCUMIN; UNINDEXED DRUG;

ABSENCE OF SIDE EFFECTS; ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BLADDER CANCER; BLOOD BRAIN BARRIER; BONE CANCER; BRAIN CANCER; BREAST CANCER; CANCER CELL; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER RADIOTHERAPY; CANCER SURVIVAL; CAUSE OF DEATH; CELL CYCLE; CELL INVASION; CELL PROLIFERATION; CELL SURVIVAL; CHEMOPROPHYLAXIS; CHRONIC FATIGUE SYNDROME; CLINICAL TRIAL; COLORECTAL CANCER; COMBINATION CHEMOTHERAPY; CYTOTOXICITY; DEGENERATIVE DISEASE; DEPRESSION; DIET THERAPY; DRUG CONJUGATION; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG METABOLISM; DRUG POTENTIATION; ESOPHAGUS CANCER; ESOPHAGUS RESECTION; FATIGUE; HUMAN; INTESTINE CANCER; KIDNEY CARCINOMA; LEUKEMIA; LIVER CELL CARCINOMA; LUNG CANCER; LYMPHOMA; MELANOMA; MONOTHERAPY; MOUTH CANCER; MULTIPLE MYELOMA; NEUROPATHIC PAIN; NEUROPROTECTION; NONHUMAN; OVARY CANCER; PANCREAS CANCER; PRIORITY JOURNAL; PROSTATE CANCER; STOMACH CANCER; THYMUS CANCER; UTERINE CERVIX CANCER; UTERUS CANCER;

ANTINEOPLASTIC AGENTS; CURCUMIN; DRUG DELIVERY SYSTEMS; HUMANS; NEOPLASMS; PAIN; PLANT EXTRACTS; SIGNAL TRANSDUCTION;

CURCUMA LONGA;

EID: 45849149639     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2008.03.025     Document Type: Article

References (282)

1. (accessed 01.02.08).
2. Goel A., Kunnumakkara A.B., and Aggarwal B.B. Curcumin as Curecumin: from kitchen to clinic. Biochem. Pharmacol. (2007)
3. L.A.G. Ries, D. Melbert, M. Krapcho, A. Mariotto, B.A. Miller, E.J. Feuer, L. Clegg, M.J. Horner, N. Howlader, M.P. Eisner, M. Reichman, B.K. Edwards (Eds.), SEER Cancer Statistics Review, 1975-2004, National Cancer Institute, Bethesda, MD. Available from: , based on November 2006 SEER data submission, posted to the SEER web site, 2007.
4. Jemal A., Siegel R., Ward E., Murray T., Xu J., and Thun M.J. Cancer statistics, 2007. CA Cancer J. Clin. 57 (2007) 43-66
5. Widakowich C., de Azambula E., Gil T., Dinh P., Awada A., and Piccart-Gebhart M. Molecular targeted therapies in breast cancer: where are we now?. Int. J. Biochem. Cell Biol. 39 (2007) 1375-1387
6. Wicha M.S., Liu S., and Dontu G. Cancer stem cells: an old idea - a paradigm shift. Cancer Res. 66 (2006) 1883-1890 discussion 1895-1886
7. Aggarwal B.B., Bhatt I.D., Ichikawa H., Ahn K.S., Sethi G., Sandur S.K., Sundaram C., Seeram N., and Shishodia S. Curcumin - biological and medicinal properties. In: Ravindran P.N., Babu K.N., and Sivaraman K. (Eds). Turmeric the Genus Curcuma (2007), CRC Press, NY 297-368
8. Shao Z.M., Shen Z.Z., Liu C.H., Sartippour M.R., Go V.L., Heber D., and Nguyen M. Curcumin exerts multiple suppressive effects on human breast carcinoma cells. Int. J. Cancer 98 (2002) 234-240
9. Schindler R., and Mentlein R. Flavonoids and vitamin E reduce the release of the angiogenic peptide vascular endothelial growth factor from human tumor cells. J. Nutr. 136 (2006) 1477-1482
10. Holy J.M. Curcumin disrupts mitotic spindle structure and induces micronucleation in MCF-7 breast cancer cells. Mutat. Res. 518 (2002) 71-84
11. Ramachandran C., Fonseca H.B., Jhabvala P., Escalon E.A., and Melnick S.J. Curcumin inhibits telomerase activity through human telomerase reverse transcriptase in MCF-7 breast cancer cell line. Cancer Lett. 184 (2002) 1-6
12. Di G.H., Li H.C., Shen Z.Z., and Shao Z.M. Analysis of anti-proliferation of curcumin on human breast cancer cells and its mechanism. Zhonghua Yi Xue Za Zhi 83 (2003) 1764-1768
13. Bobrovnikova-Marjon E.V., Marjon P.L., Barbash O., Vander Jagt D.L., and Abcouwer S.F. Expression of angiogenic factors vascular endothelial growth factor and interleukin-8/CXCL8 is highly responsive to ambient glutamine availability: role of nuclear factor-kappaB and activating protein-1. Cancer Res. 64 (2004) 4858-4869
14. Aggarwal B.B., Shishodia S., Takada Y., Banerjee S., Newman R.A., Bueso-Ramos C.E., and Price J.E. Curcumin suppresses the paclitaxel-induced nuclear factor-kappaB pathway in breast cancer cells and inhibits lung metastasis of human breast cancer in nude mice. Clin. Cancer Res. 11 (2005) 7490-7498
15. Yoon H., and Liu R.H. Effect of selected phytochemicals and apple extracts on NF-kappaB activation in human breast cancer MCF-7 cells. J. Agric. Food Chem. 55 (2007) 3167-3173
16. Bachmeier B.E., Mohrenz I.V., Mirisola V., Schleicher E., Romeo F., Hohneke C., Jochum M., Nerlich A.G., and Pfeffer U. Curcumin down-regulates the inflammatory cytokines CXCL1 and -2 in breast cancer cells via NF{kappa}B. Carcinogenesis (2007)
17. Hammamieh R., Sumaida D., Zhang X., Das R., and Jett M. Control of the growth of human breast cancer cells in culture by manipulation of arachidonate metabolism. BMC Cancer 7 (2007) 138
18. Aggarwal B.B., Banerjee S., Bharadwaj U., Sung B., Shishodia S., and Sethi G. Curcumin induces the degradation of cyclin E expression through ubiquitin-dependent pathway and up-regulates cyclin-dependent kinase inhibitors p21 and p27 in multiple human tumor cell lines. Biochem. Pharmacol. 73 (2007) 1024-1032
19. Xia X., Cheng G., Pan Y., Xia Z.H., and Kong L.D. Behavioral, neurochemical, neuroendocrine effects of the ethanolic extract from Curcuma longa L.in the mouse forced swimming test. J. Ethnopharmacol. 110 (2007) 356-363
20. Zhang H.G., Kim H., Liu C., Yu S., Wang J., Grizzle W.E., Kimberly R.P., and Barnes S. Curcumin reverses breast tumor exosomes mediated immune suppression of NK cell tumor cytotoxicity. Biochim. Biophys. Acta 1773 (2007) 1116-1123
21. Poma P., Notarbartolo M., Labbozzetta M., Maurici A., Carina V., Alaimo A., Rizzi M., Simoni D., and D'Alessandro N. The antitumor activities of curcumin and of its isoxazole analogue are not affected by multiple gene expression changes in an MDR model of the MCF-7 breast cancer cell line: analysis of the possible molecular basis. Int. J. Mol. Med. 20 (2007) 329-335
22. Tomida M., Ohtake H., Yokota T., Kobayashi Y., and Kurosumi M. Stat3 up-regulates expression of nicotinamide N-methyltransferase in human cancer cells. J. Cancer Res. Clin. Oncol. (2007)
23. Dutta S., Padhye S., Priyadarsini K.I., and Newton C. Antioxidant and antiproliferative activity of curcumin semicarbazone. Bioorg. Med. Chem. Lett. 15 (2005) 2738-2744
24. Abas F., Hui L.S., Ahmad S., Stanslas J., Israf D.A., Shaari K., and Lajis N.H. Biological evaluation of curcumin and related diarylheptanoids. Z. Naturforsch. C 61 (2006) 625-631
25. Salmaso S., Bersani S., Semenzato A., and Caliceti P. New cyclodextrin bioconjugates for active tumour targeting. J. Drug Target 15 (2007) 379-390
26. Sun A., Shoji M., Lu Y.J., Liotta D.C., and Snyder J.P. Synthesis of EF24-tripeptide chloromethyl ketone: a novel curcumin-related anticancer drug delivery system. J. Med. Chem. 49 (2006) 3153-3158
27. Somasundaram S., Edmund N.A., Moore D.T., Small G.W., Shi Y.Y., and Orlowski R.Z. Dietary curcumin inhibits chemotherapy-induced apoptosis in models of human breast cancer. Cancer Res. 62 (2002) 3868-3875
28. Liao Z., Cox J.D., and Komaki R. Radiochemotherapy of esophageal cancer. J. Thorac. Oncol. 2 (2007) 553-568
29. Rafiee P., Ogawa H., Heidemann J., Li M.S., Aslam M., Lamirand T.H., Fisher P.J., Graewin S.J., Dwinell M.B., Johnson C.P., Shaker R., and Binion D.G. Isolation and characterization of human esophageal microvascular endothelial cells: mechanisms of inflammatory activation. Am. J. Physiol. Gastrointest. Liver Physiol. 285 (2003) G1277-G1292
30. Wax A., Pyhtila J.W., Graf R.N., Nines R., Boone C.W., Dasari R.R., Feld M.S., Steele V.E., and Stoner G.D. Prospective grading of neoplastic change in rat esophagus epithelium using angle-resolved low-coherence interferometry. J. Biomed. Opt. 10 (2005) 051604
31. Valentini V., and Cellini F. Radiotherapy in gastric cancer: a systematic review of literature and new perspectives. Expert Rev. Anticancer Ther. 10 (2007) 1379-1393
32. Siewert J.R., Stein H.J., and von Rahden B.H. Multimodal treatment of gastrointestinal tract tumors: consequences for surgery. World J. Surg. 29 (2005) 940-948
33. Churchill M., Chadburn A., Bilinski R.T., and Bertagnolli M.M. Inhibition of intestinal tumors by curcumin is associated with changes in the intestinal immune cell profile. J. Surg. Res. 89 (2000) 169-175
34. Tunstall R.G., Sharma R.A., Perkins S., Sale S., Singh R., Farmer P.B., Steward W.P., and Gescher A.J. Cyclooxygenase-2 expression and oxidative DNA adducts in murine intestinal adenomas: modification by dietary curcumin and implications for clinical trials. Eur. J. Cancer 42 (2006) 415-421
35. Almhanna K., Kalmadi S., Pelley R., and Kim R. Neoadjuvant therapy for hepatocellular carcinoma: is there an optimal approach?. Oncology (Williston Park) 21 (2007) 1116-1122 discussion 1122, 1124, 1127-1118
36. White E.L., Ross L.J., Schmid S.M., Kelloff G.J., Steele V.E., and Hill D.L. Screening of potential cancer preventing chemicals for induction of glutathione in rat liver cells. Oncol. Rep. 5 (1998) 507-512
37. Vietri M., Pietrabissa A., Mosca F., Spisni R., and Pacifici G.M. Curcumin is a potent inhibitor of phenol sulfotransferase (SULT1A1) in human liver and extrahepatic tissues. Xenobiotica 33 (2003) 357-363
38. 2-terminal kinase signaling pathways in human hepatoma HepG2 cells. Br. J. Pharmacol. 140 (2003) 461-470
39. Labbozzetta M., Notarbartolo M., Poma P., Giannitrapani L., Cervello M., Montalto G., and D'Alessandro N. Significance of autologous interleukin-6 production in the HA22T/VGH cell model of hepatocellular carcinoma. Ann. NY Acad. Sci. 1089 (2006) 268-275
40. Bae M.K., Kim S.H., Jeong J.W., Lee Y.M., Kim H.S., Kim S.R., Yun I., Bae S.K., and Kim K.W. Curcumin inhibits hypoxia-induced angiogenesis via down-regulation of HIF-1. Oncol. Rep. 15 (2006) 1557-1562
41. Choi H., Chun Y.S., Kim S.W., Kim M.S., and Park J.W. Curcumin inhibits hypoxia-inducible factor-1 by degrading aryl hydrocarbon receptor nuclear translocator: a mechanism of tumor growth inhibition. Mol. Pharmacol. 70 (2006) 1664-1671
42. Cao J., Liu Y., Jia L., Zhou H.M., Kong Y., Yang G., Jiang L.P., Li Q.J., and Zhong L.F. Curcumin induces apoptosis through mitochondrial hyperpolarization and mtDNA damage in human hepatoma G2 cells. Free Radic. Biol. Med. 43 (2007) 968-975
43. Aggarwal B.B., Kumar A., and Bharti A.C. Anticancer potential of curcumin: preclinical and clinical studies. Anticancer Res. 23 (2003) 363-398
44. Wang W., Abbruzzese J.L., Evans D.B., Larry L., Cleary K.R., and Chiao P.J. The nuclear factor-kappa B RelA transcription factor is constitutively activated in human pancreatic adenocarcinoma cells. Clin. Cancer Res. 5 (1999) 119-127
45. Li L., Aggarwal B.B., Shishodia S., Abbruzzese J., and Kurzrock R. Nuclear factor-kappaB and IkappaB kinase are constitutively active in human pancreatic cells, and their down-regulation by curcumin (diferuloylmethane) is associated with the suppression of proliferation and the induction of apoptosis. Cancer 101 (2004) 2351-2362
46. Khanbolooki S., Nawrocki S.T., Arumugam T., Andtbacka R., Pino M.S., Kurzrock R., Logsdon C.D., Abbruzzese J.L., and McConkey D.J. Nuclear factor-kappaB maintains TRAIL resistance in human pancreatic cancer cells. Mol. Cancer Ther. 5 (2006) 2251-2260
47. Kamohara H., Takahashi M., Ishiko T., Ogawa M., and Baba H. Induction of interleukin-8 (CXCL-8) by tumor necrosis factor-alpha and leukemia inhibitory factor in pancreatic carcinoma cells: impact of CXCL-8 as an autocrine growth factor. Int. J. Oncol. 31 (2007) 627-632
48. Starr A.N., Vexler A., Marmor S., Konik D., Ashkenasi-Voghera M., Lev-Ari S., Greif Y., and Ben-Yosef R. Establishment and characterization of a pancreatic carcinoma cell line derived from malignant pleural effusion. Oncology 69 (2005) 239-245
49. Lev-Ari S., Strier L., Kazanov D., Madar-Shapiro L., Dvory-Sobol H., Pinchuk I., Marian B., Lichtenberg D., and Arber N. Celecoxib and curcumin synergistically inhibit the growth of colorectal cancer cells. Clin. Cancer Res. 11 (2005) 6738-6744
50. Lev-Ari S., Starr A., Vexler A., Karaush V., Loew V., Greif J., Fenig E., Aderka D., and Ben-Yosef R. Inhibition of pancreatic and lung adenocarcinoma cell survival by curcumin is associated with increased apoptosis, down-regulation of COX-2 and EGFR and inhibition of Erk1/2 activity. Anticancer Res. 26 (2006) 4423-4430
51. Wang Z., Zhang Y., Banerjee S., Li Y., and Sarkar F.H. Notch-1 down-regulation by curcumin is associated with the inhibition of cell growth and the induction of apoptosis in pancreatic cancer cells. Cancer 106 (2006) 2503-2513
52. Lev-Ari S., Vexler A., Starr A., Ashkenazy-Voghera M., Greif J., Aderka D., and Ben-Yosef R. Curcumin augments gemcitabine cytotoxic effect on pancreatic adenocarcinoma cell lines. Cancer Invest. 25 (2007) 411-418
53. Holcomb B., Yip-Schneider M.T., Matos J.M., Dixon J., Kennard J., Mahomed J., Shanmugam R., Sebolt-Leopold J., and Schmidt C.M. Pancreatic cancer cell genetics and signaling response to treatment correlate with efficacy of gemcitabine-based molecular targeting strategies. J. Gastrointest. Surg. (2007)
54. Anand P., Kunnumakkara A.B., Newman R.A., and Aggarwal B.B. Bioavailability of curcumin: problems and promises. Mol. Pharmacol. 4 (2007) 807-818
55. Li L., Braiteh F.S., and Kurzrock R. Liposome-encapsulated curcumin: in vitro and in vivo effects on proliferation, apoptosis, signaling, and angiogenesis. Cancer 104 (2005) 1322-1331
56. Dhillon N., Aggarwal B.B., Newman R.A., Wolff R.A., Kunnumakkara A.B., Abbruzzese J.L., Hong D.S., Camacho L.H., Ng C., and Kurzrock R. Curcumin and pancreatic cancer: phase II clinical trial experience. J. Clin. Oncol. 25 (2007) 4599
57. Wei S.C., Lin Y.S., Tsao P.N., Wu-Tsai J.J., Wu C.H., and Wong J.M. Comparison of the anti-proliferation and apoptosis-induction activities of sulindac, celecoxib, curcumin, and nifedipine in mismatch repair-deficient cell lines. J. Formos. Med. Assoc. 103 (2004) 599-606
58. Rashmi R., Santhosh Kumar T.R., and Karunagaran D. Human colon cancer cells differ in their sensitivity to curcumin-induced apoptosis and heat shock protects them by inhibiting the release of apoptosis-inducing factor and caspases. FEBS Lett. 538 (2003) 19-24
59. Scott D.W., and Loo G. Curcumin-induced GADD153 gene up-regulation in human colon cancer cells. Carcinogenesis 25 (2004) 2155-2164
60. Rashmi R., Kumar S., and Karunagaran D. Ectopic expression of Hsp70 confers resistance and silencing its expression sensitizes human colon cancer cells to curcumin-induced apoptosis. Carcinogenesis 25 (2004) 179-187
61. 2+/calmodulin function. Chem. Biol. 11 (2004) 1455-1463
62. Rashmi R., Kumar S., and Karunagaran D. Ectopic expression of Bcl-XL or Ku70 protects human colon cancer cells (SW480) against curcumin-induced apoptosis while their down-regulation potentiates it. Carcinogenesis 25 (2004) 1867-1877
63. Rashmi R., Kumar S., and Karunagaran D. Human colon cancer cells lacking Bax resist curcumin-induced apoptosis and Bax requirement is dispensable with ectopic expression of Smac or downregulation of Bcl-xL. Carcinogenesis 26 (2005) 713-723
64. Du B., Jiang L., Xia Q., and Zhong L. Synergistic inhibitory effects of curcumin and 5-fluorouracil on the growth of the human colon cancer cell line HT-29. Chemotherapy 52 (2006) 23-28
65. Moussavi M., Assi K., Gomez-Munoz A., and Salh B. Curcumin mediates ceramide generation via the de novo pathway in colon cancer cells. Carcinogenesis 27 (2006) 1636-1644
66. Collett G.P., and Campbell F.C. Curcumin induces c-jun N-terminal kinase-dependent apoptosis in HCT116 human colon cancer cells. Carcinogenesis 25 (2004) 2183-2189
67. Jeong W.S., Kim I.W., Hu R., and Kong A.N. Modulation of AP-1 by natural chemopreventive compounds in human colon HT-29 cancer cell line. Pharm. Res. 21 (2004) 649-660
68. Chen A., Xu J., and Johnson A.C. Curcumin inhibits human colon cancer cell growth by suppressing gene expression of epidermal growth factor receptor through reducing the activity of the transcription factor Egr-1. Oncogene 25 (2006) 278-287
69. Wang X., Wang Q., Ives K.L., and Evers B.M. Curcumin inhibits neurotensin-mediated interleukin-8 production and migration of HCT116 human colon cancer cells. Clin. Cancer Res. 12 (2006) 5346-5355
70. Lev-Ari S., Maimon Y., Strier L., Kazanov D., and Arber N. Down-regulation of prostaglandin E2 by curcumin is correlated with inhibition of cell growth and induction of apoptosis in human colon carcinoma cell lines. J. Soc. Integr. Oncol. 4 (2006) 21-26
71. Su C.C., Chen G.W., Lin J.G., Wu L.T., and Chung J.G. Curcumin inhibits cell migration of human colon cancer colo 205 cells through the inhibition of nuclear factor kappa B/p65 and down-regulates cyclooxygenase-2 and matrix metalloproteinase-2 expressions. Anticancer Res. 26 (2006) 1281-1288
72. Naganuma M., Saruwatari A., Okamura S., and Tamura H. Turmeric and curcumin modulate the conjugation of 1-naphthol in Caco-2 cells. Biol. Pharm. Bull. 29 (2006) 1476-1479
73. Reddy S., Rishi A.K., Xu H., Levi E., Sarkar F.H., and Majumdar A.P. Mechanisms of curcumin- and EGF-receptor related protein (ERRP)-dependent growth inhibition of colon cancer cells. Nutr. Cancer 55 (2006) 185-194
74. Patel B.B., Sengupta R., Qazi S., Vachhani H., Yu Y., Rishi A.K., and Majumdar A.P. Curcumin enhances the effects of 5-fluorouracil and oxaliplatin in mediating growth inhibition of colon cancer cells by modulating EGFR and IGF-1R. Int. J. Cancer 122 (2008) 267-273
75. Telang N., and Katdare M. Combinatorial prevention of carcinogenic risk in a model for familial colon cancer. Oncol. Rep. 17 (2007) 909-914
76. Hsu Y.C., Weng H.C., Lin S., and Chien Y.W. Curcuminoids-cellular uptake by human primary colon cancer cells as quantitated by a sensitive HPLC assay and its relation with the inhibition of proliferation and apoptosis. J. Agric. Food Chem. 55 (2007) 8213-8222
77. Li L., Ahmed B., Mehta K., and Kurzrock R. Liposomal curcumin with and without oxaliplatin: effects on cell growth, apoptosis, and angiogenesis in colorectal cancer. Mol. Cancer Ther. 6 (2007) 1276-1282
78. Howells L.M., Mitra A., and Manson M.M. Comparison of oxaliplatin- and curcumin-mediated antiproliferative effects in colorectal cell lines. Int. J. Cancer 121 (2007) 175-183
79. Tamvakopoulos C., Dimas K., Sofianos Z.D., Hatziantoniou S., Han Z., Liu Z.L., Wyche J.H., and Pantazis P. Metabolism and anticancer activity of the curcumin analogue, dimethoxycurcumin. Clin. Cancer Res. 13 (2007) 1269-1277
80. Wargovich M.J., Chen C.D., Jimenez A., Steele V.E., Velasco M., Stephens L.C., Price R., Gray K., and Kelloff G.J. Aberrant crypts as a biomarker for colon cancer: evaluation of potential chemopreventive agents in the rat. Cancer Epidemiol. Biomarkers Prev. 5 (1996) 355-360
81. Wijnands M.V., van Erk M.J., Doornbos R.P., Krul C.A., and Woutersen R.A. Do aberrant crypt foci have predictive value for the occurrence of colorectal tumours? Potential of gene expression profiling in tumours. Food Chem. Toxicol. 42 (2004) 1629-1639
82. Volate S.R., Davenport D.M., Muga S.J., and Wargovich M.J. Modulation of aberrant crypt foci and apoptosis by dietary herbal supplements (quercetin, curcumin, silymarin, ginseng and rutin). Carcinogenesis 26 (2005) 1450-1456
83. Xu G., Huang W., Zhang W.M., Lai Z.S., He M.R., Wang Y.D., and Zhang Y.L. Effects of combined use of curcumin and catechin on cyclooxygenase-2 mRNA expression in dimethylhydrazine-induced rat colon carcinogenesis. Di Yi Jun Yi Da Xue Xue Bao 25 (2005) 48-52
84. Kwon Y., and Magnuson B.A. Effect of azoxymethane and curcumin on transcriptional levels of cyclooxygenase-1 and -2 during initiation of colon carcinogenesis. Scand. J. Gastroenterol. 42 (2007) 72-80
85. Devasena T., Rajasekaran K.N., Gunasekaran G., Viswanathan P., and Menon V.P. Anticarcinogenic effect of bis-1,7-(2-hydroxyphenyl)-hepta-1,6-diene-3,5-dione a curcumin analog on DMH-induced colon cancer model. Pharmacol. Res. 47 (2003) 133-140
86. Devasena T., Menon V.P., and Rajasekharan K.N. Prevention of 1,2-dimethylhydrazine-induced circulatory oxidative stress by bis-1,7-(2-hydroxyphenyl)-hepta-1,6-diene-3,5-dione during colon carcinogenesis. Pharmacol. Rep. 58 (2006) 229-235
87. von der Maase H. Current and future perspectives in advanced bladder cancer: is there a new standard?. Semin. Oncol. 29 (2002) 3-14
88. Sun M., Yang Y., Li H., Su B., Lu Y., Wei Q., and Fan T. [The effect of curcumin on bladder cancer cell line EJ in vitro]. Zhong Yao Cai 27 (2004) 848-850
89. Kamat A.M., Sethi G., and Aggarwal B.B. Curcumin potentiates the apoptotic effects of chemotherapeutic agents and cytokines through down-regulation of nuclear factor-kappaB and nuclear factor-kappaB-regulated gene products in IFN-alpha-sensitive and IFN-alpha-resistant human bladder cancer cells. Mol. Cancer Ther. 6 (2007) 1022-1030
90. Park C., Kim G.Y., Kim G.D., Choi B.T., Park Y.M., and Choi Y.H. Induction of G2/M arrest and inhibition of cyclooxygenase-2 activity by curcumin in human bladder cancer T24 cells. Oncol. Rep. 15 (2006) 1225-1231
91. Lu P., Tong Q., Jiang F., Zheng L., Chen F., Zeng F., Dong J., and Du Y. Preparation of curcumin prodrugs and their in vitro anti-tumor activities. J. Huazhong Univ. Sci. Technolog. Med. Sci. 25 (2005) 668-670, 67
92. Tong Q.S., Zheng L.D., Lu P., Jiang F.C., Chen F.M., Zeng F.Q., Wang L., and Dong J.H. Apoptosis-inducing effects of curcumin derivatives in human bladder cancer cells. Anticancer Drugs 17 (2006) 279-287
93. Jiang M.C., Yang-Yen H.F., Yen J.J., and Lin J.K. Curcumin induces apoptosis in immortalized NIH 3T3 and malignant cancer cell lines. Nutr. Cancer 26 (1996) 111-120
94. Chen X., Hasuma T., Yano Y., Yoshimata T., Morishima Y., Wang Y., and Otani S. Inhibition of farnesyl protein transferase by monoterpene, curcumin derivatives and gallotannin. Anticancer Res. 17 (1997) 2555-2564
95. Ramsewak R.S., DeWitt D.L., and Nair M.G. Cytotoxicity, antioxidant and anti-inflammatory activities of curcumins I-III from Curcuma longa. Phytomedicine 7 (2000) 303-308
96. 2)-induced peroxidation of microsomal membrane lipids and DNA damage. Teratog. Carcinog. Mutagen. Suppl. 1 (2003) 151-160
97. Woo J.H., Kim Y.H., Choi Y.J., Kim D.G., Lee K.S., Bae J.H., Min D.S., Chang J.S., Jeong Y.J., Lee Y.H., Park J.W., and Kwon T.K. Molecular mechanisms of curcumin-induced cytotoxicity: induction of apoptosis through generation of reactive oxygen species, down-regulation of Bcl-XL and IAP, the release of cytochrome c and inhibition of Akt. Carcinogenesis 24 (2003) 1199-1208
98. Jung E.M., Lim J.H., Lee T.J., Park J.W., Choi K.S., and Kwon T.K. Curcumin sensitizes tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis through reactive oxygen species-mediated upregulation of death receptor 5 (DR5). Carcinogenesis 26 (2005) 1905-1913
99. Frank N., Knauft J., Amelung F., Nair J., Wesch H., and Bartsch H. No prevention of liver and kidney tumors in Long-Evans Cinnamon rats by dietary curcumin, but inhibition at other sites and of metastases. Mutat. Res. 523-524 (2003) 127-135
100. Shenouda N.S., Zhou C., Browning J.D., Ansell P.J., Sakla M.S., Lubahn D.B., and Macdonald R.S. Phytoestrogens in common herbs regulate prostate cancer cell growth in vitro. Nutr. Cancer 49 (2004) 200-208
101. Guo H., Yu J.H., Chen K., and Ye Z.Q. [Curcumin-induced the expression of inhibitor kappaBalpha protein in human prostate cancer cells]. Zhonghua Wai Ke Za Zhi 44 (2006) 1256-1259
102. Shankar S., Chen Q., Sarva K., Siddiqui I., and Srivastava R.K. Curcumin enhances the apoptosis-inducing potential of TRAIL in prostate cancer cells: molecular mechanisms of apoptosis, migration and angiogenesis. J. Mol. Signal. 2 (2007) 10
103. Shi P., Chen W.W., Hu X.Y., Yu C.X., Zhang P.J., Jiang A.L., and Zhang J.Y. Up-regulates the expression of maspin gene in prostate cancer cell line LNCaP. Yao Xue Xue Bao 41 (2006) 1152-1156
104. Ghosh J. Inhibition of arachidonate 5-lipoxygenase triggers prostate cancer cell death through rapid activation of c-Jun N-terminal kinase. Biochem. Biophys. Res. Commun. 307 (2003) 342-349
105. Deeb D., Xu Y.X., Jiang H., Gao X., Janakiraman N., Chapman R.A., and Gautam S.C. Curcumin (diferuloyl-methane) enhances tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in LNCaP prostate cancer cells. Mol. Cancer Ther. 2 (2003) 95-103
106. Deeb D., Jiang H., Gao X., Hafner M.S., Wong H., Divine G., Chapman R.A., Dulchavsky S.A., and Gautam S.C. Curcumin sensitizes prostate cancer cells to tumor necrosis factor-related apoptosis-inducing ligand/Apo2L by inhibiting nuclear factor-kappaB through suppression of IkappaBalpha phosphorylation. Mol. Cancer Ther. 3 (2004) 803-812
107. Deeb D.D., Jiang H., Gao X., Divine G., Dulchavsky S.A., and Gautam S.C. Chemosensitization of hormone-refractory prostate cancer cells by curcumin to TRAIL-induced apoptosis. J. Exp. Ther. Oncol. 5 (2005) 81-91
108. Dorai T., Dutcher J.P., Dempster D.W., and Wiernik P.H. Therapeutic potential of curcumin in prostate cancer-V: interference with the osteomimetic properties of hormone refractory C4-2B prostate cancer cells. Prostate 60 (2004) 1-17
109. Marcu M.G., Jung Y.J., Lee S., Chung E.J., Lee M.J., Trepel J., and Neckers L. Curcumin is an inhibitor of p300 histone acetyltransferase. Med. Chem. 2 (2006) 169-174
110. Zhang H.N., Yu C.X., Zhang P.J., Chen W.W., Jiang A.L., Kong F., Deng J.T., Zhang J.Y., and Young C.Y. Curcumin downregulates homeobox gene NKX3.1 in prostate cancer cell LNCaP. Acta Pharmacol. Sin. 28 (2007) 423-430
111. Nonn L., Duong D., and Peehl D.M. Chemopreventive anti-inflammatory activities of curcumin and other phytochemicals mediated by MAP kinase phosphatase-5 in prostate cells. Carcinogenesis 28 (2007) 1188-1196
112. Fernandez-Martinez A.B., Collado B., Bajo A.M., Sanchez-Chapado M., Prieto J.C., and Carmena M.J. Vasoactive intestinal peptide induces cyclooxygenase-2 expression through nuclear factor-kappaB in human prostate cell lines differential time-dependent responses in cancer progression. Mol. Cell Endocrinol. 270 (2007) 8-16
113. 2+ signalling. Implications in angiogenesis and neuroendocrine differentiation. Biochim. Biophys. Acta 1744 (2005) 224-233
114. Park J.I., Lee M.G., Cho K., Park B.J., Chae K.S., Byun D.S., Ryu B.K., Park Y.K., and Chi S.G. Transforming growth factor-beta1 activates interleukin-6 expression in prostate cancer cells through the synergistic collaboration of the Smad2, p38-NF-kappaB, JNK, and Ras signaling pathways. Oncogene 22 (2003) 4314-4332
115. Li M., Zhang Z., Hill D.L., Wang H., and Zhang R. Curcumin, a dietary component, has anticancer, chemosensitization, and radiosensitization effects by down-regulating the MDM2 oncogene through the PI3K/mTOR/ETS2 pathway. Cancer Res. 67 (2007) 1988-1996
116. Chaudhary L.R., and Hruska K.A. Inhibition of cell survival signal protein kinase B/Akt by curcumin in human prostate cancer cells. J. Cell. Biochem. 89 (2003) 1-5
117. 6] sensitizes human prostate cancer cells to tumor necrosis factor-related apoptosis-inducing ligand/Apo2L-induced apoptosis by suppressing nuclear factor-kappaB via inhibition of the prosurvival Akt signaling pathway. J. Pharmacol. Exp. Ther. 321 (2007) 616-625
118. Kumar A.P., Garcia G.E., Ghosh R., Rajnarayanan R.V., Alworth W.L., and Slaga T.J. 4-Hydroxy-3-methoxybenzoic acid methyl ester: a curcumin derivative targets Akt/NF kappa B cell survival signaling pathway: potential for prostate cancer management. Neoplasia 5 (2003) 255-266
119. Lin L., Shi Q., Nyarko A.K., Bastow K.F., Wu C.C., Su C.Y., Shih C.C., and Lee K.H. Antitumor agents. 250. Design and synthesis of new curcumin analogues as potential anti-prostate cancer agents. J. Med. Chem. 49 (2006) 3963-3972
120. Lin L., Shi Q., Su C.Y., Shih C.C., and Lee K.H. Antitumor agents 247. New 4-ethoxycarbonylethyl curcumin analogs as potential antiandrogenic agents. Bioorg. Med. Chem. 14 (2006) 2527-2534
121. Adams B.K., Cai J., Armstrong J., Herold M., Lu Y.J., Sun A., Snyder J.P., Liotta D.C., Jones D.P., and Shoji M. EF24, a novel synthetic curcumin analog, induces apoptosis in cancer cells via a redox-dependent mechanism. Anticancer Drugs 16 (2005) 263-275
122. Ohtsu H., Xiao Z., Ishida J., Nagai M., Wang H.K., Itokawa H., Su C.Y., Shih C., Chiang T., Chang E., Lee Y., Tsai M.Y., Chang C., and Lee K.H. Antitumor agents. 217. Curcumin analogues as novel androgen receptor antagonists with potential as anti-prostate cancer agents. J. Med. Chem. 45 (2002) 5037-5042
123. Jankun J., Aleem A.M., Malgorzewicz S., Szkudlarek M., Zavodszky M.I., Dewitt D.L., Feig M., Selman S.H., and Skrzypczak-Jankun E. Synthetic curcuminoids modulate the arachidonic acid metabolism of human platelet 12-lipoxygenase and reduce sprout formation of human endothelial cells. Mol. Cancer Ther. 5 (2006) 1371-1382
124. Kim J.H., Xu C., Keum Y.S., Reddy B., Conney A., and Kong A.N. Inhibition of EGFR signaling in human prostate cancer PC-3 cells by combination treatment with beta-phenylethyl isothiocyanate and curcumin. Carcinogenesis 27 (2006) 475-482
125. Khor T.O., Keum Y.S., Lin W., Kim J.H., Hu R., Shen G., Xu C., Gopalakrishnan A., Reddy B., Zheng X., Conney A.H., and Kong A.N. Combined inhibitory effects of curcumin and phenethyl isothiocyanate on the growth of human PC-3 prostate xenografts in immunodeficient mice. Cancer Res. 66 (2006) 613-621
126. Hong J.H., Ahn K.S., Bae E., Jeon S.S., and Choi H.Y. The effects of curcumin on the invasiveness of prostate cancer in vitro and in vivo. Prostate Cancer Prostatic Dis. 9 (2006) 147-152
127. Roy M., Chakraborty S., Siddiqi M., and Bhattacharya R.K. Induction of apoptosis in tumor cells by natural phenolic compounds. Asian Pac. J. Cancer Prev. 3 (2002) 61-67
128. Chearwae W., Anuchapreeda S., Nandigama K., Ambudkar S.V., and Limtrakul P. Biochemical mechanism of modulation of human P-glycoprotein (ABCB1) by curcumin I, II, and III purified from turmeric powder. Biochem. Pharmacol. 68 (2004) 2043-2052
129. Venkatraman M., Anto R.J., Nair A., Varghese M., and Karunagaran D. Biological and chemical inhibitors of NF-kappaB sensitize SiHa cells to cisplatin-induced apoptosis. Mol. Carcinog. 44 (2005) 51-59
130. Divya C.S., and Pillai M.R. Antitumor action of curcumin in human papillomavirus associated cells involves downregulation of viral oncogenes, prevention of NFkB and AP-1 translocation, and modulation of apoptosis. Mol. Carcinog. 45 (2006) 320-332
131. Limtrakul P., Chearwae W., Shukla S., Phisalphong C., and Ambudkar S.V. Modulation of function of three ABC drug transporters, P-glycoprotein (ABCB1), mitoxantrone resistance protein (ABCG2) and multidrug resistance protein 1 (ABCC1) by tetrahydrocurcumin, a major metabolite of curcumin. Mol. Cell. Biochem. 296 (2007) 85-95
132. Burger R.A., Sill M.W., Monk B.J., Greer B.E., and Sorosky J.I. Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study. J. Clin. Oncol. 25 (2007) 5165-5171
133. Syu W.J., Shen C.C., Don M.J., Ou J.C., Lee G.H., and Sun C.M. Cytotoxicity of curcuminoids and some novel compounds from Curcuma zedoaria. J. Nat. Prod. 61 (1998) 1531-1534
134. Guo F., and Xu C.J. Progress on the study of mechanism of the direct action of TCM bioactive components on ovarian cancer. Zhongguo Zhong Xi Yi Jie He Za Zhi 25 (2005) 1140-1144
135. Nakagawa-Goto K., Yamada K., Nakamura S., Chen T.H., Chiang P.C., Bastow K.F., Wang S.C., Spohn B., Hung M.C., Lee F.Y., Lee F.C., and Lee K.H. Antitumor agents. 258. Syntheses and evaluation of dietary antioxidant-taxoid conjugates as novel cytotoxic agents. Bioorg. Med. Chem. Lett. 17 (2007) 5204-5209
136. Zheng L.D., Tong Q.S., and Wu C.H. Inhibitory effects of curcumin on apoptosis of human ovary cancer cell line A2780 and its molecular mechanism. Ai Zheng 21 (2002) 1296-1300
137. Zheng L.D., Tong Q.S., and Wu C.H. Growth inhibition and apoptosis inducing mechanisms of curcumin on human ovarian cancer cell line A2780. Chin. J. Integr. Med. 12 (2006) 126-131
138. Zheng L., Tong Q., and Wu C. Growth-inhibitory effects of curcumin on ovary cancer cells and its mechanisms. J. Huazhong. Univ. Sci. Technolog. Med. Sci. 24 (2004) 55-58
139. Shi M., Cai Q., Yao L., Mao Y., Ming Y., and Ouyang G. Antiproliferation and apoptosis induced by curcumin in human ovarian cancer cells. Cell Biol. Int. 30 (2006) 221-226
140. Weir N.M., Selvendiran K., Kutala V.K., Tong L., Vishwanath S., Rajaram M., Tridandapani S., Anant S., and Kuppusamy P. Curcumin induces G2/M arrest and apoptosis in cisplatin-resistant human ovarian cancer cells by modulating Akt and p38 MAPK. Cancer Biol. Ther. 6 (2007) 178-184
141. Wahl H., Tan L., Griffith K., Choi M., and Liu J.R. Curcumin enhances Apo2L/TRAIL-induced apoptosis in chemoresistant ovarian cancer cells. Gynecol. Oncol. 105 (2007) 104-112
142. Lin Y.G., Kunnumakkara A.B., Nair A., Merritt W.M., Han L.Y., Armaiz-Pena G.N., Kamat A.A., Spannuth W.A., Gershenson D.M., Lutgendorf S.K., Aggarwal B.B., and Sood A.K. Curcumin inhibits tumor growth and angiogenesis in ovarian carcinoma by targeting the nuclear factor-kappaB pathway. Clin. Cancer Res. 13 (2007) 3423-3430
143. Homesley H.D., Filiaci V., Markman M., Bitterman P., Eaton L., Kilgore L.C., Monk B.J., and Ueland F.R. Phase III trial of ifosfamide with or without paclitaxel in advanced uterine carcinosarcoma: a Gynecologic Oncology Group Study. J. Clin. Oncol. 25 (2007) 526-531
144. Yu Z., and Shah D.M. Curcumin down-regulates Ets-1 and Bcl-2 expression in human endometrial carcinoma HEC-1-A cells. Gynecol. Oncol. 106 (2007) 541-548
145. Kenny P.M., King M.T., Viney R.C., Boyer M.J., Pollicino C.A., McLean J.M., Fulham M.J., and McCaughan B.C. Quality of life and survival in the 2 years after surgery for non small-cell lung cancer. J. Clin. Oncol. 26 (2008) 233-241
146. White E.L., Ross L.J., Schmid S.M., Kelloff G.J., Steele V.E., and Hill D.L. Screening of potential cancer-preventing chemicals for inhibition of induction of ornithine decarboxylase in epithelial cells from rat trachea. Oncol. Rep. 5 (1998) 717-722
147. Ichiki K., Mitani N., Doki Y., Hara H., Misaki T., and Saiki I. Regulation of activator protein-1 activity in the mediastinal lymph node metastasis of lung cancer. Clin. Exp. Metastasis 18 (2000) 539-545
148. Chen Y.S., Ho C.C., Cheng K.C., Tyan Y.S., Hung C.F., Tan T.W., and Chung J.G. Curcumin inhibited the arylamines N-acetyltransferase activity, gene expression and DNA adduct formation in human lung cancer cells (A549). Toxicol. In Vitro 17 (2003) 323-333
149. Radhakrishna Pillai G., Srivastava A.S., Hassanein T.I., Chauhan D.P., and Carrier E. Induction of apoptosis in human lung cancer cells by curcumin. Cancer Lett. 208 (2004) 163-170
150. Zhang J., Qi H., and Wu C. Research of anti-proliferation of curcumin on A549 human lung cancer cells and its mechanism. Zhong Yao Cai 27 (2004) 923-927
151. Lee J., Im Y.H., Jung H.H., Kim J.H., Park J.O., Kim K., Kim W.S., Ahn J.S., Jung C.W., Park Y.S., Kang W.K., and Park K. Curcumin inhibits interferon-alpha induced NF-kappaB and COX-2 in human A549 non-small cell lung cancer cells. Biochem. Biophys. Res. Commun. 334 (2005) 313-318
152. Lee J., Jung H.H., Im Y.H., Kim J.H., Park J.O., Kim K., Kim W.S., Ahn J.S., Jung C.W., Park Y.S., Kang W.K., and Park K. Interferon-alpha resistance can be reversed by inhibition of IFN-alpha-induced COX-2 expression potentially via STAT1 activation in A549 cells. Oncol. Rep. 15 (2006) 1541-1549
153. Sen S., Sharma H., and Singh N. Curcumin enhances Vinorelbine mediated apoptosis in NSCLC cells by the mitochondrial pathway. Biochem. Biophys. Res. Commun. 331 (2005) 1245-1252
154. Pesic M., Markovic J.Z., Jankovic D., Kanazir S., Markovic I.D., Rakic L., and Ruzdijic S. Induced resistance in the human non small cell lung carcinoma (NCI-H460) cell line in vitro by anticancer drugs. J. Chemother. 18 (2006) 66-73
155. Deshpande S.S., and Maru G.B. Effects of curcumin on the formation of benzo[a]pyrene derived DNA adducts in vitro. Cancer Lett. 96 (1995) 71-80
156. Blot W.J., McLaughlin J.K., Winn D.M., Austin D.F., Greenberg R.S., Preston-Martin S., Bernstein L., Schoenberg J.B., Stemhagen A., and Fraumeni Jr. J.F. Smoking and drinking in relation to oral and pharyngeal cancer. Cancer Res. 48 (1988) 3282-3287
157. Atsumi T., Fujisawa S., and Tonosaki K. Relationship between intracellular ROS production and membrane mobility in curcumin- and tetrahydrocurcumin-treated human gingival fibroblasts and human submandibular gland carcinoma cells. Oral Dis. 11 (2005) 236-242
158. Atsumi T., Tonosaki K., and Fujisawa S. Induction of early apoptosis and ROS-generation activity in human gingival fibroblasts (HGF) and human submandibular gland carcinoma (HSG) cells treated with curcumin. Arch. Oral Biol. 51 (2006) 913-921
159. D'Ambrosio S.M., Gibson-D'Ambrosio R., Milo G.E., Casto B., Kelloff G.J., and Steele V.E. Differential response of normal, premalignant and malignant human oral epithelial cells to growth inhibition by chemopreventive agents. Anticancer Res. 20 (2000) 2273-2280
160. Rinaldi A.L., Morse M.A., Fields H.W., Rothas D.A., Pei P., Rodrigo K.A., Renner R.J., and Mallery S.R. Curcumin activates the aryl hydrocarbon receptor yet significantly inhibits (-)-benzo(a)pyrene-7R-trans-7,8-dihydrodiol bioactivation in oral squamous cell carcinoma cells and oral mucosa. Cancer Res. 62 (2002) 5451-5456
161. Khafif A., Hurst R., Kyker K., Fliss D.M., Gil Z., and Medina J.E. Curcumin: a new radio-sensitizer of squamous cell carcinoma cells. Otolaryngol. Head Neck Surg. 132 (2005) 317-321
162. Atsumi T., Murakami Y., Shibuya K., Tonosaki K., and Fujisawa S. Induction of cytotoxicity and apoptosis and inhibition of cyclooxygenase-2 gene expression, by curcumin and its analog, alpha-diisoeugenol. Anticancer Res. 25 (2005) 4029-4036
163. Sharma C., Kaur J., Shishodia S., Aggarwal B.B., and Ralhan R. Curcumin down regulates smokeless tobacco-induced NF-kappaB activation and COX-2 expression in human oral premalignant and cancer cells. Toxicology 228 (2006) 1-15
164. Yokoi K., Matsuguma H., Nakahara R., Kondo T., Kamiyama Y., Mori K., and Miyazawa N. Multidisciplinary treatment for advanced invasive thymoma with cisplatin, doxorubicin, and methylprednisolone. J. Thorac. Oncol. 2 (2007) 73-78
165. Jurrmann N., Brigelius-Flohe R., and Bol G.F. Curcumin blocks interleukin-1 (IL-1) signaling by inhibiting the recruitment of the IL-1 receptor-associated kinase IRAK in murine thymoma EL-4 cells. J. Nutr. 135 (2005) 1859-1864
166. Bhattacharyya S., Mandal D., Sen G.S., Pal S., Banerjee S., Lahiry L., Finke J.H., Tannenbaum C.S., Das T., and Sa G. Tumor-induced oxidative stress perturbs nuclear factor-kappaB activity-augmenting tumor necrosis factor-alpha-mediated T-cell death: protection by curcumin. Cancer Res. 67 (2007) 362-370
167. Liu Y., Chang R.L., Cui X.X., Newmark H.L., and Conney A.H. Synergistic effects of curcumin on all-trans retinoic acid- and 1 alpha,25-dihydroxyvitamin D3-induced differentiation in human promyelocytic leukemia HL-60 cells. Oncol Res. 9 (1997) 19-29
168. Sokoloski J.A., Shyam K., and Sartorelli A.C. Induction of the differentiation of HL-60 promyelocytic leukemia cells by curcumin in combination with low levels of vitamin D3. Oncol Res. 9 (1997) 31-39
169. Pan M.H., Chang W.L., Lin-Shiau S.Y., Ho C.T., and Lin J.K. Induction of apoptosis by garcinol and curcumin through cytochrome c release and activation of caspases in human leukemia HL-60 cells. J. Agric. Food Chem. 49 (2001) 1464-1474
170. Bielak-Mijewska A., Piwocka K., Magalska A., and Sikora E. P-glycoprotein expression does not change the apoptotic pathway induced by curcumin in HL-60 cells. Cancer Chemother. Pharmacol. 53 (2004) 179-185
171. Mukherjee Nee Chakraborty S., Ghosh U., Bhattacharyya N.P., Bhattacharya R.K., Dey S., and Roy M. Curcumin-induced apoptosis in human leukemia cell HL-60 is associated with inhibition of telomerase activity. Mol. Cell. Biochem. 297 (2007) 31-39
172. Pae H.O., Jeong S.O., Jeong G.S., Kim K.M., Kim H.S., Kim S.A., Kim Y.C., Kang S.D., Kim B.N., and Chung H.T. Curcumin induces pro-apoptotic endoplasmic reticulum stress in human leukemia HL-60 cells. Biochem. Biophys. Res. Commun. 353 (2007) 1040-1045
173. Chen Y., Wu Y., He J., and Chen W. The experimental and clinical study on the effect of curcumin on cell cycle proteins and regulating proteins of apoptosis in acute myelogenous leukemia. J. Huazhong Univ. Sci. Technolog. Med. Sci. 22 (2002) 295-298
174. Chen J., Wanming D., Zhang D., Liu Q., and Kang J. Water-soluble antioxidants improve the antioxidant and anticancer activity of low concentrations of curcumin in human leukemia cells. Pharmazie 60 (2005) 57-61
175. Tan T.W., Tsai H.R., Lu H.F., Lin H.L., Tsou M.F., Lin Y.T., Tsai H.Y., Chen Y.F., and Chung J.G. Curcumin-induced cell cycle arrest and apoptosis in human acute promyelocytic leukemia HL-60 cells via MMP changes and caspase-3 activation. Anticancer Res. 26 (2006) 4361-4371
176. Chen J., Bai H., Wang C., and Kang J. Trichostatin A improves the anticancer activity of low concentrations of curcumin in human leukemia cells. Pharmazie 61 (2006) 710-716
177. Sun C.Y., Liu X.Y., Chen Y., Liu F., and Wang Y. [Experimental study on anticancer effect of curcumin on Raji cells in vitro]. Zhongguo Zhong Xi Yi Jie He Za Zhi 24 (2004) 1003-1006
178. Liu H.L., Chen Y., Cui G.H., and Zhou J.F. Curcumin, a potent anti-tumor reagent, is a novel histone deacetylase inhibitor regulating B-NHL cell line Raji proliferation. Acta Pharmacol. Sin. 26 (2005) 603-609
179. Wu Q., Chen Y., and Li X. HDAC1 expression and effect of curcumin on proliferation of Raji cells. J. Huazhong Univ. Sci. Technolog. Med. Sci. 26 (2006) 199-201 210
180. Chen Y., Shu W., Chen W., Wu Q., Liu H., and Cui G. Curcumin, both histone deacetylase and p300/CBP-specific inhibitor, represses the activity of nuclear factor kappa B and Notch 1 in Raji cells. Basic Clin. Pharmacol. Toxicol. 101 (2007) 427-433
181. Blasius R., Reuter S., Henry E., Dicato M., and Diederich M. Curcumin regulates signal transducer and activator of transcription (STAT) expression in K562 cells. Biochem. Pharmacol. 72 (2006) 1547-1554
182. Chakraborty S., Ghosh U., Bhattacharyya N.P., Bhattacharya R.K., and Roy M. Inhibition of telomerase activity and induction of apoptosis by curcumin in K-562 cells. Mutat. Res. 596 (2006) 81-90
183. Singhal S.S., Awasthi S., Pandya U., Piper J.T., Saini M.K., Cheng J.Z., and Awasthi Y.C. The effect of curcumin on glutathione-linked enzymes in K562 human leukemia cells. Toxicol. Lett. 109 (1999) 87-95
184. Duvoix A., Morceau F., Delhalle S., Schmitz M., Schnekenburger M., Galteau M.M., Dicato M., and Diederich M. Induction of apoptosis by curcumin: mediation by glutathione S-transferase P1-1 inhibition. Biochem. Pharmacol. 66 (2003) 1475-1483
185. Rajasingh J., Raikwar H.P., Muthian G., Johnson C., and Bright J.J. Curcumin induces growth-arrest and apoptosis in association with the inhibition of constitutively active JAK-STAT pathway in T cell leukemia. Biochem. Biophys. Res. Commun. 340 (2006) 359-368
186. Tomita M., Kawakami H., Uchihara J.N., Okudaira T., Masuda M., Takasu N., Matsuda T., Ohta T., Tanaka Y., Ohshiro K., Mori N., and NF-kappaB C.(d.) i.c.a. leading to suppression of cell growth of human T-cell leukemia virus type I-infected T-cell lines and primary adult T-cell leukemia cells. Int. J. Cancer 118 (2006) 765-772
187. Jiang D.Z., Xie Q.Y., and Wang Q.R. Effect of curcumin on the proliferation of murine CFU-GM and WEHI-3B cells. Hunan Yi Ke Da Xue Xue Bao 25 (2000) 216-218
188. Chen W.H., Chen Y., Cui G.H., Gu J.X., Hu D., Chen W.K., and Li X.G. Effect of curcumin on STAT5 signaling pathway in primary CML cells. Zhongguo Shi Yan Xue Ye Xue Za Zhi 12 (2004) 572-576
189. Martin-Cordero C., Lopez-Lazaro M., Galvez M., and Ayuso M.J. Curcumin as a DNA topoisomerase II poison. J. Enzyme Inhib. Med. Chem. 18 (2003) 505-509
190. Kellner C., and Zunino S.J. Nitric oxide is synthesized in acute leukemia cells after exposure to phenolic antioxidants and initially protects against mitochondrial membrane depolarization. Cancer Lett. 215 (2004) 43-52
191. Bhaumik S., Jyothi M.D., and Khar A. Differential modulation of nitric oxide production by curcumin in host macrophages and NK cells. FEBS Lett. 483 (2000) 78-82
192. Anuchapreeda S., Limtrakul P., Thanarattanakorn P., Sittipreechacharn S., and Chanarat P. Inhibitory effect of curcumin on WT1 gene expression in patient leukemic cells. Arch. Pharm. Res. 29 (2006) 80-87
193. Piwocka K., Jaruga E., Skierski J., Gradzka I., and Sikora E. Effect of glutathione depletion on caspase-3 independent apoptosis pathway induced by curcumin in Jurkat cells. Free Radic. Biol. Med. 31 (2001) 670-678
194. Sikora E., Bielak-Zmijewska A., Magalska A., Piwocka K., Mosieniak G., Kalinowska M., Widlak P., Cymerman I.A., and Bujnicki J.M. Curcumin induces caspase-3-dependent apoptotic pathway but inhibits DNA fragmentation factor 40/caspase-activated DNase endonuclease in human Jurkat cells. Mol. Cancer Ther. 5 (2006) 927-934
195. Wolanin K., Magalska A., Mosieniak G., Klinger R., McKenna S., Vejda S., Sikora E., and Piwocka K. Curcumin affects components of the chromosomal passenger complex and induces mitotic catastrophe in apoptosis-resistant Bcr-Abl-expressing cells. Mol. Cancer Res. 4 (2006) 457-469
196. Zambre A.P., Kulkarni V.M., Padhye S., Sandur S.K., and Aggarwal B.B. Novel curcumin analogs targeting TNF-induced NF-kappaB activation and proliferation in human leukemic KBM-5 cells. Bioorg. Med. Chem. 14 (2006) 7196-7204
197. Polasa K., Naidu A.N., Ravindranath I., and Krishnaswamy K. Inhibition of B(a)P induced strand breaks in presence of curcumin. Mutat. Res. 557 (2004) 203-213
198. Anuchapreeda S., Thanarattanakorn P., Sittipreechacharn S., Tima S., Chanarat P., and Limtrakul P. Inhibitory effect of curcumin on MDR1 gene expression in patient leukemic cells. Arch. Pharm. Res. 29 (2006) 866-873
199. Wu Y., Chen Y., Xu J., and Lu L. Anticancer activities of curcumin on human Burkitt's lymphoma. Zhonghua Zhong Liu Za Zhi 24 (2002) 348-352
200. Thompson K.H., Bohmerle K., Polishchuk E., Martins C., Toleikis P., Tse J., Yuen V., McNeill J.H., and Orvig C. Complementary inhibition of synoviocyte, smooth muscle cell or mouse lymphoma cell proliferation by a vanadyl curcumin complex compared to curcumin alone. J. Inorg. Biochem. 98 (2004) 2063-2070
201. Skommer J., Wlodkowic D., and Pelkonen J. Cellular foundation of curcumin-induced apoptosis in follicular lymphoma cell lines. Exp. Hematol. 34 (2006) 463-474
202. Uddin S., Hussain A.R., Manogaran P.S., Al-Hussein K., Platanias L.C., Gutierrez M.I., and Bhatia K.G. Curcumin suppresses growth and induces apoptosis in primary effusion lymphoma. Oncogene 24 (2005) 7022-7030
203. Gururajan M., Dasu T., Shahidain S., Jennings C.D., Robertson D.A., Rangnekar V.M., and Bondada S. Spleen tyrosine kinase (Syk), a novel target of curcumin, is required for B lymphoma growth. J. Immunol. 178 (2007) 111-121
204. Thomas R.K., Sos M.L., Zander T., Mani O., Popov A., Berenbrinker D., Smola-Hess S., Schultze J.L., and Wolf J. Inhibition of nuclear translocation of nuclear factor-kappaB despite lack of functional IkappaBalpha protein overcomes multiple defects in apoptosis signaling in human B-cell malignancies. Clin. Cancer Res. 11 (2005) 8186-8194
205. Liu B., Bai Q.X., Chen X.Q., Gao G.X., and Gu H.T. [Effect of curcumin on expression of survivin, Bcl-2 and Bax in human multiple myeloma cell line]. Zhongguo Shi Yan Xue Ye Xue Za Zhi 15 (2007) 762-766
206. Wang Y.D., Hu Y., and Sun C.Y. [Inhibitory effect of curcumin on angiogenesis induced by brain derived neurotrophic factor from multiple myeloma cells]. Zhongguo Shi Yan Xue Ye Xue Za Zhi 14 (2006) 70-74
207. Iersel M.L., Ploemen J.P., Struik I., van Amersfoort C., Keyzer A.E., Schefferlie J.G., and van Bladeren P.J. Inhibition of glutathione S-transferase activity in human melanoma cells by alpha,beta-unsaturated carbonyl derivatives. Effects of acrolein, cinnamaldehyde, citral, crotonaldehyde, curcumin, ethacrynic acid, and trans-2-hexenal. Chem. Biol. Interact. 102 (1996) 117-132
208. Siwak D.R., Shishodia S., Aggarwal B.B., and Kurzrock R. Curcumin-induced antiproliferative and proapoptotic effects in melanoma cells are associated with suppression of IkappaB kinase and nuclear factor kappaB activity and are independent of the B-Raf/mitogen-activated/extracellular signal-regulated protein kinase pathway and the Akt pathway. Cancer 104 (2005) 879-890
209. Marin Y.E., Wall B.A., Wang S., Namkoong J., Martino J.J., Suh J., Lee H.J., Rabson A.B., Yang C.S., Chen S., and Ryu J.H. Curcumin downregulates the constitutive activity of NF-kappaB and induces apoptosis in novel mouse melanoma cells. Melanoma Res. 17 (2007) 274-283
210. Ray S., Chattopadhyay N., Mitra A., Siddiqi M., and Chatterjee A. Curcumin exhibits antimetastatic properties by modulating integrin receptors, collagenase activity, and expression of Nm23 and E-cadherin. J. Environ. Pathol. Toxicol. Oncol. 22 (2003) 49-58
211. Banerji A., Chakrabarti J., Mitra A., and Chatterjee A. Effect of curcumin on gelatinase A (MMP-2) activity in B16F10 melanoma cells. Cancer Lett. 211 (2004) 235-242
212. Depeille P., Cuq P., Mary S., Passagne I., Evrard A., Cupissol D., and Vian L. Glutathione S-transferase M1 and multidrug resistance protein 1 act in synergy to protect melanoma cells from vincristine effects. Mol. Pharmacol. 65 (2004) 897-905
213. Depeille P., Cuq P., Passagne I., Evrard A., and Vian L. Combined effects of GSTP1 and MRP1 in melanoma drug resistance. Br. J. Cancer 93 (2005) 216-223
214. Anto R.J., Maliekal T.T., and Karunagaran D. L-929 cells harboring ectopically expressed RelA resist curcumin-induced apoptosis. J. Biol. Chem. 275 (2000) 15601-15604
215. Kondo A., Mogi M., Koshihara Y., and Togari A. Signal transduction system for interleukin-6 and interleukin-11 synthesis stimulated by epinephrine in human osteoblasts and human osteogenic sarcoma cells. Biochem. Pharmacol. 61 (2001) 319-326
216. Periyasamy S., and Sanchez E.R. Antagonism of glucocorticoid receptor transactivity and cell growth inhibition by transforming growth factor-beta through AP-1-mediated transcriptional repression. Int. J. Biochem. Cell Biol. 34 (2002) 1571-1585
217. Kwak H.J., Park M.J., Cho H., Park C.M., Moon S.I., Lee H.C., Park I.C., Kim M.S., Rhee C.H., and Hong S.I. Transforming growth factor-beta1 induces tissue inhibitor of metalloproteinase-1 expression via activation of extracellular signal-regulated kinase and Sp1 in human fibrosarcoma cells. Mol. Cancer Res. 4 (2006) 209-220
218. Walters D.K., Muff R., Langsam B., Born W., and Fuchs B. Cytotoxic effects of curcumin on osteosarcoma cell lines. Invest. New Drugs (2007)
219. Navis I., Sriganth P., and Premalatha B. Dietary curcumin with cisplatin administration modulates tumour marker indices in experimental fibrosarcoma. Pharmacol. Res. 39 (1999) 175-179
220. Kumar Mitra A., and Krishna M. In vivo modulation of signaling factors involved in cell survival. J. Radiat. Res. (Tokyo) 45 (2004) 491-495
221. Ambegaokar S.S., Wu L., Alamshahi K., Lau J., Jazayeri L., Chan S., Khanna P., Hsieh E., and Timiras P.S. Curcumin inhibits dose-dependently and time-dependently neuroglial cell proliferation and growth. Neuro. Endocrinol. Lett. 24 (2003) 469-473
222. Nagai S., Kurimoto M., Washiyama K., Hirashima Y., Kumanishi T., and Endo S. Inhibition of cellular proliferation and induction of apoptosis by curcumin in human malignant astrocytoma cell lines. J. Neurooncol. 74 (2005) 105-111
223. Karmakar S., Banik N.L., and Ray S.K. Curcumin suppressed anti-apoptotic signals and activated cysteine proteases for apoptosis in human malignant glioblastoma U87MG cells. Neurochem. Res. 32 (2007) 2103-2113
224. Dhandapani K.M., Mahesh V.B., and Brann D.W. Curcumin suppresses growth and chemoresistance of human glioblastoma cells via AP-1 and NFkappaB transcription factors. J. Neurochem. 102 (2007) 522-538
225. Kim S.Y., Jung S.H., and Kim H.S. Curcumin is a potent broad spectrum inhibitor of matrix metalloproteinase gene expression in human astroglioma cells. Biochem. Biophys. Res. Commun. 337 (2005) 510-516
226. Woo M.S., Jung S.H., Kim S.Y., Hyun J.W., Ko K.H., Kim W.K., and Kim H.S. Curcumin suppresses phorbol ester-induced matrix metalloproteinase-9 expression by inhibiting the PKC to MAPK signaling pathways in human astroglioma cells. Biochem. Biophys. Res. Commun. 335 (2005) 1017-1025
227. Gao X., Deeb D., Jiang H., Liu Y.B., Dulchavsky S.A., and Gautam S.C. Curcumin differentially sensitizes malignant glioma cells to TRAIL/Apo2L-mediated apoptosis through activation of procaspases and release of cytochrome c from mitochondria. J. Exp. Ther. Oncol. 5 (2005) 39-48
228. Belkaid A., Copland I.B., Massillon D., and Annabi B. Silencing of the human microsomal glucose-6-phosphate translocase induces glioma cell death: potential new anticancer target for curcumin. FEBS Lett. 580 (2006) 3746-3752
229. Karmakar S., Banik N.L., Patel S.J., and Ray S.K. Curcumin activated both receptor-mediated and mitochondria-mediated proteolytic pathways for apoptosis in human glioblastoma T98G cells. Neurosci. Lett. 407 (2006) 53-58
230. Kang S.K., Cha S.H., and Jeon H.G. Curcumin-induced histone hypoacetylation enhances caspase-3-dependent glioma cell death and neurogenesis of neural progenitor cells. Stem Cells Dev. 15 (2006) 165-174
231. Liu E., Wu J., Cao W., Zhang J., Liu W., Jiang X., and Zhang X. Curcumin induces G2/M cell cycle arrest in a p53-dependent manner and upregulates ING4 expression in human glioma. J. Neurooncol. 85 (2007) 263-270
232. Shinojima N., Yokoyama T., Kondo Y., and Kondo S. Roles of the Akt/mTOR/p70S6K and ERK1/2 signaling pathways in curcumin-induced autophagy. Autophagy 6 (2007) 635-637
233. Aoki H., Takada Y., Kondo S., Sawaya R., Aggarwal B.B., and Kondo Y. Evidence that curcumin suppresses the growth of malignant gliomas in vitro and in vivo through induction of autophagy: role of Akt and extracellular signal-regulated kinase signaling pathways. Mol. Pharmacol. 72 (2007) 29-39
234. Cleeland C.S., Bennett G.J., Dantzer R., Dougherty P.M., Dunn A.J., Meyers C.A., Miller A.H., Payne R., Reuben J.M., Wang X.S., and Lee B.N. Are the symptoms of cancer and cancer treatment due to a shared biologic mechanism? A cytokine-immunologic model of cancer symptoms. Cancer 97 (2003) 2919-2925
235. Chen H.W., Yu S.L., Chen J.J., Li H.N., Lin Y.C., Yao P.L., Chou H.Y., Chien C.T., Chen W.J., Lee Y.T., and Yang P.C. Anti-invasive gene expression profile of curcumin in lung adenocarcinoma based on a high throughput microarray analysis. Mol. Pharmacol. 65 (2004) 99-110
236. Dantzer R. Cytokine-induced sickness behavior: mechanisms and implications. Ann. NY Acad. Sci. 933 (2001) 222-234
237. Dantzer R., and Kelley K.W. Twenty years of research on cytokine-induced sickness behavior. Brain Behav. Immun. 21 (2007) 153-160
238. Wagner R., and Myers R.R. Endoneurial injection of TNF-alpha produces neuropathic pain behaviors. Neuroreport 7 (1996) 2897-2901
239. DeLeo J.A., and Yezierski R.P. The role of neuroinflammation and neuroimmune activation in persistent pain. Pain 90 (2001) 1-6
240. Watkins L.R., Goehler L.E., Relton J., Brewer M.T., and Maier S.F. Mechanisms of tumor necrosis factor-alpha (TNF-alpha) hyperalgesia. Brain Res. 692 (1995) 244-250
241. Opree A., and Kress M. Involvement of the proinflammatory cytokines tumor necrosis factor-alpha, IL-1 beta, and IL-6 but not IL-8 in the development of heat hyperalgesia: effects on heat-evoked calcitonin gene-related peptide release from rat skin. J. Neurosci. 20 (2000) 6289-6293
242. Kress M., and Reeh P.W. More sensory competence for nociceptive neurons in culture. Proc. Natl. Acad. Sci. USA 93 (1996) 14995-14997
243. Cata J.P., Weng H.R., Lee B.N., Reuben J.M., and Dougherty P.M. Clinical and experimental findings in humans and animals with chemotherapy-induced peripheral neuropathy. Minerva Anestesiol. 72 (2006) 151-169
244. Sommer C., and Kress M. Recent findings on how proinflammatory cytokines cause pain: peripheral mechanisms in inflammatory and neuropathic hyperalgesia. Neurosci. Lett. 361 (2004) 184-187
245. Richardson P.G., Briemberg H., Jagannath S., Wen P.Y., Barlogie B., Berenson J., Singhal S., Siegel D.S., Irwin D., Schuster M., Srkalovic G., Alexanian R., Rajkumar S.V., Limentani S., Alsina M., Orlowski R.Z., Najarian K., Esseltine D., Anderson K.C., and Amato A.A. Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. J. Clin. Oncol. 24 (2006) 3113-3120
246. Cata J.P., Weng H.R., Burton A.W., Villareal H., Giralt S., and Dougherty P.M. Quantitative sensory findings in patients with bortezomib-induced pain. J. Pain 8 (2007) 296-306
247. Sharma S., Kulkarni S.K., Agrewala J.N., and Chopra K. Curcumin attenuates thermal hyperalgesia in a diabetic mouse model of neuropathic pain. Eur. J. Pharmacol. 536 (2006) 256-261
248. Chen H., Noble F., Coric P., Fournie-Zaluski M.C., and Roques B.P. Aminophosphinic inhibitors as transition state analogues of enkephalin-degrading enzymes: a class of central analgesics. Proc. Natl. Acad. Sci. USA 95 (1998) 12028-12033
249. Lanquillon S., Krieg J.C., Bening-Abu-Shach U., and Vedder H. Cytokine production and treatment response in major depressive disorder. Neuropsychopharmacology 22 (2000) 370-379
250. Covelli A. Modulation of multidrug resistance (MDR) in hematological malignancies. Ann. Oncol. 10 Suppl. 6 (1999) 53-59
251. Budziszewska B., Jaworska-Feil L., Tetich M., Basta-Kaim A., Kubera M., Leskiewicz M., and Lason W. Regulation of the human corticotropin-releasing-hormone gene promoter activity by antidepressant drugs in Neuro-2A and AtT-20 cells. Neuropsychopharmacology 29 (2004) 785-794
252. Wichers M.C., Koek G.H., Robaeys G., Praamstra A.J., and Maes M. Early increase in vegetative symptoms predicts IFN-alpha-induced cognitive-depressive changes. Psychol. Med. 35 (2005) 433-441
253. Musselman D.L., Miller A.H., Porter M.R., Manatunga A., Gao F., Penna S., Pearce B.D., Landry J., Glover S., McDaniel J.S., and Nemeroff C.B. Higher than normal plasma interleukin-6 concentrations in cancer patients with depression: preliminary findings. Am. J. Psychiatry 158 (2001) 1252-1257
254. Kagaya A., Kugaya A., Takebayashi M., Fukue-Saeki M., Saeki T., Yamawaki S., and Uchitomi Y. Plasma concentrations of interleukin-1beta, interleukin-6, soluble interleukin-2 receptor and tumor necrosis factor alpha of depressed patients in Japan. Neuropsychobiology 43 (2001) 59-62
255. Spath-Schwalbe E., Lange T., Perras B., Fehm H.L., and Born J. Interferon-alpha acutely impairs sleep in healthy humans. Cytokine 12 (2000) 518-521
256. Yu Z.F., Kong L.D., and Chen Y. Antidepressant activity of aqueous extracts of Curcuma longa in mice. J. Ethnopharmacol. 83 (2002) 161-165
257. Xu Y., Ku B.S., Yao H.Y., Lin Y.H., Ma X., Zhang Y.H., and Li X.J. The effects of curcumin on depressive-like behaviors in mice. Eur. J. Pharmacol. 518 (2005) 40-46
258. Mazzio E.A., Harris N., and Soliman K.F. Food constituents attenuate monoamine oxidase activity and peroxide levels in C6 astrocyte cells. Planta Med. 64 (1998) 603-606
259. Xu Y., Ku B.S., Yao H.Y., Lin Y.H., Ma X., Zhang Y.H., and Li X.J. Antidepressant effects of curcumin in the forced swim test and olfactory bulbectomy models of depression in rats. Pharmacol. Biochem. Behav. 82 (2005) 200-206
260. Xu Y., Ku B., Cui L., Li X., Barish P.A., Foster T.C., and Ogle W.O. Curcumin reverses impaired hippocampal neurogenesis and increases serotonin receptor 1A mRNA and brain-derived neurotrophic factor expression in chronically stressed rats. Brain Res. 1162 (2007) 9-18
261. Xia X., Pan Y., Zhang W.Y., Cheng G., and Kong L.D. Ethanolic extracts from Curcuma longa attenuates behavioral, immune, and neuroendocrine alterations in a rat chronic mild stress model. Biol. Pharm. Bull. 29 (2006) 938-944
262. Meyers C.A., Albitar M., and Estey E. Cognitive impairment, fatigue, and cytokine levels in patients with acute myelogenous leukemia or myelodysplastic syndrome. Cancer 104 (2005) 788-793
263. Bower J.E., Ganz P.A., Aziz N., and Fahey J.L. Fatigue and proinflammatory cytokine activity in breast cancer survivors. Psychosom. Med. 64 (2002) 604-611
264. Bower J.E., Ganz P.A., Aziz N., lmstead R., Irwin M.R., and Cole S.W. Inflammatory responses to psychological stress in fatigued breast cancer survivors: relationship to glucocorticoids. Brain Behav. Immun. 21 (2007) 251-258
265. Mills P.J., Parker B., Dimsdale J.E., Sadler G.R., and Ancoli-Israel S. The relationship between fatigue and quality of life and inflammation during anthracycline-based chemotherapy in breast cancer. Biol. Psychol. 69 (2005) 85-96
266. Willoughby D.S., McFarlin B., and Bois C. Interleukin-6 expression after repeated bouts of eccentric exercise. Int. J. Sports Med. 24 (2003) 15-21
267. Kurzrock R. The role of cytokines in cancer-related fatigue. Cancer 92 (2001) 1684-1688
268. Hainsworth J.D., Burris III H.A., Erland J.B., Thomas M., and Greco F.A. Phase I trial of docetaxel administered by weekly infusion in patients with advanced refractory cancer. J. Clin. Oncol. 16 (1998) 2164-2168
269. Monk J.P., Phillips G., Waite R., Kuhn J., Schaaf L.J., Otterson G.A., Guttridge D., Rhoades C., Shah M., Criswell T., Caligiuri M.A., and Villalona-Calero M.A. Assessment of tumor necrosis factor alpha blockade as an intervention to improve tolerability of dose-intensive chemotherapy in cancer patients. J. Clin. Oncol. 24 (2006) 1852-1859
270. Maes M., Mihaylova I., and Bosmans E. Not in the mind of neurasthenic lazybones but in the cell nucleus: patients with chronic fatigue syndrome have increased production of nuclear factor kappa beta. Neuro. Endocrinol. Lett. 28 (2007) 456-462
271. Kawamura I., Morishita R., Tomita N., Lacey E., Aketa M., Tsujimoto S., Manda T., Tomoi M., Kida I., Higaki J., Kaneda Y., Shimomura K., and Ogihara T. Intratumoral injection of oligonucleotides to the NF kappa B binding site inhibits cachexia in a mouse tumor model. Gene Ther. 6 (1999) 91-97
272. Baghdiguian S., Martin M., Richard I., Pons F., Astier C., Bourg N., Hay R.T., Chemaly R., Halaby G., Loiselet J., Anderson L.V., Lopez de Munain A., Fardeau M., Mangeat P., Beckmann J.S., and Lefranc G. Calpain 3 deficiency is associated with myonuclear apoptosis and profound perturbation of the IkappaB alpha/NF-kappaB pathway in limb-girdle muscular dystrophy type 2A. Nat. Med. 5 (1999) 503-511
273. Davis J.M., Murphy E.A., Carmichael M.D., Zielinski M.R., Groschwitz C.M., Brown A.S., Gangemi J.D., Ghaffar A., and Mayer E.P. Curcumin effects on inflammation and performance recovery following eccentric exercise-induced muscle damage. Am. J. Physiol. Regul. Integr. Comp. Physiol. 292 (2007) R2168-R2173
274. Wilson C.J., Finch C.E., and Cohen H.J. Cytokines and cognition - the case for a head-to-toe inflammatory paradigm. J. Am. Geriatr. Soc. 50 (2002) 2041-2056
275. Wu A., Ying Z., and Gomez-Pinilla F. Dietary curcumin counteracts the outcome of traumatic brain injury on oxidative stress, synaptic plasticity, and cognition. Exp. Neurol. 197 (2006) 309-317
276. Ng T.P., Chiam P.C., Lee T., Chua H.C., Lim L., and Kua E.H. Curry consumption and cognitive function in the elderly. Am. J. Epidemiol. 164 (2006) 898-906
277. Kumar P., Padi S.S., Naidu P.S., and Kumar A. Possible neuroprotective mechanisms of curcumin in attenuating 3-nitropropionic acid-induced neurotoxicity. Methods Find. Exp. Clin. Pharmacol. 29 (2007) 19-25
278. Sumanont Y., Murakami Y., Tohda M., Vajragupta O., Watanabe H., and Matsumoto K. Effects of manganese complexes of curcumin and diacetylcurcumin on kainic acid-induced neurotoxic responses in the rat hippocampus. Biol. Pharm. Bull. 30 (2007) 1732-1739
279. Jagota A., and Reddy M.Y. The effect of curcumin on ethanol induced changes in suprachiasmatic nucleus (SCN) and pineal. Cell. Mol. Neurobiol. 27 (2007) 997-1006
280. Kuhad A., and Chopra K. Curcumin attenuates diabetic encephalopathy in rats: behavioral and biochemical evidences. Eur. J. Pharmacol. 576 (2007) 34-42
281. Garcia-Alloza M., Borrelli L.A., Rozkalne A., Hyman B.T., and Bacskai B.J. Curcumin labels amyloid pathology in vivo, disrupts existing plaques, and partially restores distorted neurites in an Alzheimer mouse model. J. Neurochem. 102 (2007) 1095-1104
282. Ryu E.K., Choe Y.S., Lee K.H., Choi Y., and Kim B.T. Curcumin and dehydrozingerone derivatives: synthesis, radiolabeling, and evaluation for beta-amyloid plaque imaging. J. Med. Chem. 49 (2006) 6111-6119